Nathan Fowler

Nathan Fowler is a leading follicular lymphoma investigator who pioneered clinical development of PI3K delta inhibitors in indolent B-cell lymphomas. He conducted early-phase trials of idelalisib, copanlisib, umbralisib, and other PI3K pathway inhibitors that led to regulatory approvals. His research has addressed mechanisms of toxicity with PI3K inhibitors and strategies to improve their therapeutic index. He has contributed to multiple consensus guidelines for indolent lymphoma management and regularly lectures at major hematology meetings.